Compounds > n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
Page last updated: 2024-09-03

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Colonic Neoplasms

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Colonic Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arich, A; Bar-Yehuda, S; Dreznick, Z; Fishman, P; Madi, L; Ohana, G; Rath-Wolfson, L; Silberman, D; Slosman, G1
Bar-Yehuda, S; Barer, F; Erlanger, A; Fishman, P; Madi, L; Ochaion, A; Ohana, G1
Bar-Yehuda, S; Fishman, P; Gery, S; Madi, L; Shkapenuk, M; Silberman, D1
Grden, M; Kitowska, A; Maciejewska, I; Pawelczyk, T; Sakowicz-Burkiewicz, M; Szutowicz, A1

Other Studies

4 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Colonic Neoplasms

ArticleYear
Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.
    British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8

    Topics: Adenosine; Administration, Oral; Animals; Biological Availability; Carcinoma; Cell Division; Colonic Neoplasms; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Purinergic P1 Receptor Agonists; Transplantation, Heterologous; Tumor Cells, Cultured

2003
An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.
    Oncogene, 2004, Apr-01, Volume: 23, Issue:14

    Topics: Adenosine; Animals; beta Catenin; Carcinoma; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Cyclin D1; Cytoskeletal Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Humans; Indoles; Lithium; Maleimides; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins c-myc; Purinergic P1 Receptor Agonists; Pyridines; Trans-Activators

2004
CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:1

    Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Transplantation, Heterologous; Tumor Cells, Cultured

2005
Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines.
    Archives of biochemistry and biophysics, 2013, Volume: 533, Issue:1-2

    Topics: Adenosine; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Extracellular Space; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Protein Phosphatase 2; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Signal Transduction

2013